rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2026-12-21rsp-3869Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYЗначение поляризации макрофагов при иммуновоспалительных заболеваниях с поражением легких: возможности фармакотерапииMacrophage polarization in immune-inflammatory diseases with lung damage: The promising therapeutic strategieshttps://orcid.org/0000-0003-2641-9785БекетоваТ. В.BeketovaT. V.

Бекетова Татьяна Валентиновна 

121356, Москва, ул. Маршала Тимошенко, 15

115522, Москва, Каширское шоссе, 34а

107023, Москва, ул. Большая Семеновская, 38

Tatiana V. Beketova 

121359, Moscow, Marshala Timoshenko str., 19, building 1A

115522, Moscow, Kashirskoye Highway, 34A

107023, Moscow, Bolshaya Semyonovskaya str., 38

doc@tvbek.ruhttps://orcid.org/0000-0002-9146-0904ЩепихинЕ. И.ShchepikhinE. I.

107564, Москва, Яузская аллея, 2

Evgeniy I. Shchepikhin 

107564, Moscow, Yauzskaya Alley, 2

https://orcid.org/0000-0002-3248-6426АнаньеваЛ. П.AnanyevaL. P.

115522, Москва, Каширское шоссе, 34а

Lidia P. Ananyeva 

115522, Moscow, Kashirskoye Highway, 34A

ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации ; ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» ; ФГАОУ ВО «Московский политехнический университет»РоссияCentral State Medical Academy of the Administrative Directorate of the President of the Russian Federation ; V.A. Nasonova Research Institute of Rheumatology ; Moscow Polytechnic UniversityRussian FederationФГБНУ «Центральный научно-исследовательский институт туберкулеза»РоссияCentral Tuberculosis Research InstituteRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2026020320266411221Copyright © Бекетова Т.В., Щепихин Е.И., Ананьева Л.П., 20262026Бекетова Т.В., Щепихин Е.И., Ананьева Л.П.Beketova T.V., Shchepikhin E.I., Ananyeva L.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3869

Обсуждается значение поляризации макрофагов в процессах воспаления и фиброза. Целенаправленная модуляция молекул, влияющих на поляризацию альтернативно активированных макрофагов М2, может препятствовать прогрессированию фиброза. Рассматриваются перспективы лечения иммуновоспалительных заболеваний с поражением легких, направленного на функции макрофагов, включая возможности применения селективного модулятора нейропилина 2 эфзофитимода при системной склеродермии и саркоидозе, а также при других заболеваниях.

The article discusses the role of macrophage polarization in the processes of inflammation and fibrosis. Targeting the polarization of alternatively activated M2 macrophages could be a promising strategy to prevent fibrosis progression. The prospects for the treatment of immune-inflammatory diseases with lung damage, aimed at macrophage functions, are considered, including the possibilities of using the selective neuropilin 2 modulator efzophytimod in systemic sclerosis and sarcoidosis, as well as other diseases.

поляризация макрофаговфиброзсистемная склеродермиясаркоидозгиперчувствительный пневмонитАНЦА-ассоциированные системные васкулитыIgG4-связанное заболеваниеантифибротическая терапияингибиторы функции макрофаговэфзофитимодmacrophage polarizationfibrosissystemic sclerosissarcoidosishypersensitivity pneumonitisANCA-associated systemic vasculitisIgG4-related diseaseantifibrotic therapymacrophage function inhibitorsefzophytimodReferencesYona S, Gordon S. From the reticuloendothelial to mononuclear phagocyte system – The unaccounted years. Front Immunol. 2015;6:328. doi: 10.3389/fimmu.2015.00328Yona S, Gordon S. From the reticuloendothelial to mononuclear phagocyte system – The unaccounted years. Front Immunol. 2015;6:328. doi: 10.3389/fimmu.2015.00328Wu S, Zhao S, Hai L, Yang Z, Wang S, Cui D, et al. Macrophage polarization regulates the pathogenesis and progression of autoimmune diseases. Autoimmun Rev. 2025;24(7):103820. doi: 10.1016/j.autrev.2025.103820Wu S, Zhao S, Hai L, Yang Z, Wang S, Cui D, et al. Macrophage polarization regulates the pathogenesis and progression of autoimmune diseases. Autoimmun Rev. 2025;24(7):103820. doi: 10.1016/j.autrev.2025.103820Герасимова ЕВ, Попкова ТВ. Функциональные нарушения макрофагов при ревматоидном артрите и атеросклерозе. Научно-практическая ревматология. 2018;56(4):486- 493. doi: 10.14412/1995-4484-2018-486-493Gerasimova EV, Popkova TV. Macrophage functional disorders in rheumatoid arthritis and atherosclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(4):486-493 (In Russ.). doi: 10.14412/1995-4484-2018-486-493Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Anatomy of a discovery: M1 and M2 macrophages. Front Immunol. 2015;6:212. doi: 10.3389/fimmu.2015.00212Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Anatomy of a discovery: M1 and M2 macrophages. Front Immunol. 2015;6:212. doi: 10.3389/fimmu.2015.00212Cox N, Pokrovskii M, Vicario R, Geissmann F. Origins, biology, and diseases of tissue macrophages. Annu Rev Immunol. 2021;39:313-344. doi: 10.1146/annurev-immunol-093019-111748Cox N, Pokrovskii M, Vicario R, Geissmann F. Origins, biology, and diseases of tissue macrophages. Annu Rev Immunol. 2021;39:313-344. doi: 10.1146/annurev-immunol-093019-111748Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Mueller M, Wormley FL Jr. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. Infect Immun. 2015;83(12):4513-4527. doi: 10.1128/IAI.00935-15Leopold Wager CM, Hole CR, Wozniak KL, Olszewski MA, Mueller M, Wormley FL Jr. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. Infect Immun. 2015;83(12):4513-4527. doi: 10.1128/IAI.00935-15Ikushima H, Negishi H, Taniguchi T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb Symp Quant Biol. 2013;78:105-116. doi: 10.1101/sqb.2013.78.020321Ikushima H, Negishi H, Taniguchi T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb Symp Quant Biol. 2013;78:105-116. doi: 10.1101/sqb.2013.78.020321Mussbacher M, Derler M, Basilio J, Schmid JA. NF-kappaB in monocytes and macrophages – An inflammatory master regulator in multitalented immune cells. Front Immunol. 2023;14:1134661. doi: 10.3389/fimmu.2023.1134661Mussbacher M, Derler M, Basilio J, Schmid JA. NF-kappaB in monocytes and macrophages – An inflammatory master regulator in multitalented immune cells. Front Immunol. 2023;14:1134661. doi: 10.3389/fimmu.2023.1134661Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440. doi: 10.1002/jcp.26429Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440. doi: 10.1002/jcp.26429Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186-195. doi: 10.1111/imm.12910Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186-195. doi: 10.1111/imm.12910Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 2012;122:787-795. doi: 10.1172/JCI59643Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 2012;122:787-795. doi: 10.1172/JCI59643Cao Z, Sun X, Icli B, Wara AK, Feinberg MW. Role of Kruppellike factors in leukocyte development, function, and disease. Blood. 2010;116(22):4404-4414. doi: 10.1182/blood-2010-05-285353Cao Z, Sun X, Icli B, Wara AK, Feinberg MW. Role of Kruppellike factors in leukocyte development, function, and disease. Blood. 2010;116(22):4404-4414. doi: 10.1182/blood-2010-05-285353Rőszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediat Inflamm. 2015;2015:816460. doi: 10.1155/2015/816460Rőszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediat Inflamm. 2015;2015:816460. doi: 10.1155/2015/816460Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol. 2009;27:451-483. doi: 10.1146/annurev.immunol.021908.132532Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol. 2009;27:451-483. doi: 10.1146/annurev.immunol.021908.132532Furukawa S, Moriyama M, Tanaka A, Maehara T, Tsuboi H, Iizuka M, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Clin Immunol. 2015;156(1):9-18. doi: 10.1016/j.clim.2014.10.008Furukawa S, Moriyama M, Tanaka A, Maehara T, Tsuboi H, Iizuka M, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Clin Immunol. 2015;156(1):9-18. doi: 10.1016/j.clim.2014.10.008Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y, et al. Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via Toll-like receptor 7/interleukin-33 signaling. Arthritis Rheumatol. 2020;72(1):166- 178. doi: 10.1002/art.41052Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y, et al. Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via Toll-like receptor 7/interleukin-33 signaling. Arthritis Rheumatol. 2020;72(1):166- 178. doi: 10.1002/art.41052Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J, et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol. 2011;89(1):130- 142. doi: 10.1038/icb.2010.70Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J, et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol. 2011;89(1):130- 142. doi: 10.1038/icb.2010.70Song E, Ouyang N, Hörbelt M, Antus B, Wang M, Exton MS. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol. 2000;204(1):19-28. doi: 10.1006/cimm.2000.1687Song E, Ouyang N, Hörbelt M, Antus B, Wang M, Exton MS. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol. 2000;204(1):19-28. doi: 10.1006/cimm.2000.1687Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173(7):781-792. doi: 10.1164/rccm.200509-1518OCPrasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173(7):781-792. doi: 10.1164/rccm.200509-1518OCWynn TA, Barron L. Macrophages: Master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30(3):245-257. doi: 10.1055/s-0030-1255354Wynn TA, Barron L. Macrophages: Master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30(3):245-257. doi: 10.1055/s-0030-1255354Nelson DE, Olszewski MA. Editorial: Exploring the molecular mechanisms that regulate macrophage polarization. Front Immunol. 2025;16:1599215. doi: 10.3389/fimmu.2025.1599215Nelson DE, Olszewski MA. Editorial: Exploring the molecular mechanisms that regulate macrophage polarization. Front Immunol. 2025;16:1599215. doi: 10.3389/fimmu.2025.1599215Bain CC, MacDonald AS. The impact of the lung environment on macrophage development, activation and function: Diversity in the face of adversity. Mucosal Immunol. 2022;15:223-234. doi: 10.1038/s41385-021-00480-wBain CC, MacDonald AS. The impact of the lung environment on macrophage development, activation and function: Diversity in the face of adversity. Mucosal Immunol. 2022;15:223-234. doi: 10.1038/s41385-021-00480-wOsterholzer JJ, Chen GH, Olszewski MA, Zhang YM, Curtis JL, Huffnagle GB, et al. Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection. Am J Pathol. 2011;178(1):198-211. doi: 10.1016/j.ajpath.2010.11.006Osterholzer JJ, Chen GH, Olszewski MA, Zhang YM, Curtis JL, Huffnagle GB, et al. Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection. Am J Pathol. 2011;178(1):198-211. doi: 10.1016/j.ajpath.2010.11.006Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10:35. doi: 10.1186/1742-2094-10-35Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10:35. doi: 10.1186/1742-2094-10-35Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med. 2011;184(5):569-581. doi: 10.1164/rccm.201010-1719OCGibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med. 2011;184(5):569-581. doi: 10.1164/rccm.201010-1719OCScott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, et al. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: A retrospective, multicentre cohort study. Lancet Respir Med. 2019;7(6):497-508. doi: 10.1016/S2213-2600(18)30508-3Scott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, et al. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: A retrospective, multicentre cohort study. Lancet Respir Med. 2019;7(6):497-508. doi: 10.1016/S2213-2600(18)30508-3Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, et al. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2021;204(1):74-81. doi: 10.1164/rccm.202003-0669OCKreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, et al. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2021;204(1):74-81. doi: 10.1164/rccm.202003-0669OCMeziani L, Mondini M, Petit B, Boissonnas A, Thomas de Montpreville V, Mercier O, et al. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J. 2018;51(3):1702120. doi: 10.1183/13993003.02120-2017Meziani L, Mondini M, Petit B, Boissonnas A, Thomas de Montpreville V, Mercier O, et al. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J. 2018;51(3):1702120. doi: 10.1183/13993003.02120-2017Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med. 2017;214(8):2387-2404. doi: 10.1084/jem.20162152Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med. 2017;214(8):2387-2404. doi: 10.1084/jem.20162152Isshiki T, Vierhout M, Naiel S, Ali P, Yazdanshenas P, Kumaran V, et al. Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease. Biochem Pharmacol. 2023;211:115501. doi: 10.1016/j.bcp.2023.115501Isshiki T, Vierhout M, Naiel S, Ali P, Yazdanshenas P, Kumaran V, et al. Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease. Biochem Pharmacol. 2023;211:115501. doi: 10.1016/j.bcp.2023.115501Arora S, Olszewski MA, Tsang TM, McDonald RA, Toews GB, Huffnagle GB. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infection Immun. 2011;79:1915-1926. doi: 10.1128/IAI.01270-10Arora S, Olszewski MA, Tsang TM, McDonald RA, Toews GB, Huffnagle GB. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infection Immun. 2011;79:1915-1926. doi: 10.1128/IAI.01270-10Giles DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, Ponath G, Pitt D, et al. Myeloid cell plasticity in the evolution of central nervous system autoimmunity. Ann Neurol. 2018;83(1):131- 141. doi: 10.1002/ana.25128Giles DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, Ponath G, Pitt D, et al. Myeloid cell plasticity in the evolution of central nervous system autoimmunity. Ann Neurol. 2018;83(1):131- 141. doi: 10.1002/ana.25128Xu J, Ganguly A, Zhao J, Ivey M, Lopez R, Osterholzer JJ, et al. CCR2 signaling promotes brain infiltration of inflammatory monocytes and contributes to neuropathology during cryptococcal meningoencephalitis. mBio. 2021;12(4):e0107621. doi: 10.1128/mBio.01076-21Xu J, Ganguly A, Zhao J, Ivey M, Lopez R, Osterholzer JJ, et al. CCR2 signaling promotes brain infiltration of inflammatory monocytes and contributes to neuropathology during cryptococcal meningoencephalitis. mBio. 2021;12(4):e0107621. doi: 10.1128/mBio.01076-21Dhupar R, Powers AA, Eisenberg SH, Gemmill RM, Bardawil CE, Udoh HM, et al. Orchestrating resilience: How neuropilin-2 and macrophages contribute to cardiothoracic disease. J Clin Med. 2024;13(5):1446. doi: 10.3390/jcm13051446Dhupar R, Powers AA, Eisenberg SH, Gemmill RM, Bardawil CE, Udoh HM, et al. Orchestrating resilience: How neuropilin-2 and macrophages contribute to cardiothoracic disease. J Clin Med. 2024;13(5):1446. doi: 10.3390/jcm13051446Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: Multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med. 2002;12(1):13-19. doi: 10.1016/s1050-1738(01)00140-2Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: Multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med. 2002;12(1):13-19. doi: 10.1016/s1050-1738(01)00140-2Harman JL, Sayers J, Chapman C, Pellet-Many C. Emerging roles for neuropilin-2 in cardiovascular disease. Int J Mol Sci. 2020;21:5154. doi: 10.3390/ijms21145154Harman JL, Sayers J, Chapman C, Pellet-Many C. Emerging roles for neuropilin-2 in cardiovascular disease. Int J Mol Sci. 2020;21:5154. doi: 10.3390/ijms21145154Islam R, Mishra J, Bodas S, Bhattacharya S, Batra SK, Dutta S, et al. Role of neuropilin-2-mediated signaling axis in cancer progression and therapy resistance. Cancer Metastasis Rev. 2022;41(3):771-787. doi: 10.1007/s10555-022-10048-0Islam R, Mishra J, Bodas S, Bhattacharya S, Batra SK, Dutta S, et al. Role of neuropilin-2-mediated signaling axis in cancer progression and therapy resistance. Cancer Metastasis Rev. 2022;41(3):771-787. doi: 10.1007/s10555-022-10048-0Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: Identification and distribution of splice variants and soluble isoforms. Genomics. 2000;70:211-222. doi: 10.1006/geno.2000.6381Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: Identification and distribution of splice variants and soluble isoforms. Genomics. 2000;70:211-222. doi: 10.1006/geno.2000.6381Chen H, Chédotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron. 1997;19:547-559. doi: 10.1016/S0896-6273(00)80371-2Chen H, Chédotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron. 1997;19:547-559. doi: 10.1016/S0896-6273(00)80371-2Immormino RM, Lauzier DC, Nakano H, Hernandez ML, Alexis NE, Ghio AJ, et al. Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol. 2018;315(2):L202-L211. doi: 10.1152/ajplung.00067.2018Immormino RM, Lauzier DC, Nakano H, Hernandez ML, Alexis NE, Ghio AJ, et al. Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol. 2018;315(2):L202-L211. doi: 10.1152/ajplung.00067.2018Aung NY, Ohe R, Meng H, Kabasaw T, Yang S, Kato T, et al. Specific neuropilins expression in alveolar macrophages among tissue-specific macrophages. PLoS One. 2016;11:e0147358. doi: 10.1371/journal.pone.0147358Aung NY, Ohe R, Meng H, Kabasaw T, Yang S, Kato T, et al. Specific neuropilins expression in alveolar macrophages among tissue-specific macrophages. PLoS One. 2016;11:e0147358. doi: 10.1371/journal.pone.0147358Dhupar R, Jones KE, Powers AA, Eisenberg SH, Ding K, Chen F, et al. Isoforms of neuropilin-2 denote unique tumor-associated macrophages in breast cancer. Front Immunol. 2022;13:830169. doi: 10.3389/fimmu.2022.830169Dhupar R, Jones KE, Powers AA, Eisenberg SH, Ding K, Chen F, et al. Isoforms of neuropilin-2 denote unique tumor-associated macrophages in breast cancer. Front Immunol. 2022;13:830169. doi: 10.3389/fimmu.2022.830169Burman A, Tanjore H, Blackwell TS. Endoplasmic reticulum stress in pulmonary fibrosis. Matrix Biol. 2018;68-69:355-365. doi: 10.1016/j.matbio.2018.03.015Burman A, Tanjore H, Blackwell TS. Endoplasmic reticulum stress in pulmonary fibrosis. Matrix Biol. 2018;68-69:355-365. doi: 10.1016/j.matbio.2018.03.015Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, et al. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem. 2012;287(15):11629- 11641. doi: 10.1074/jbc.M111.338673Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, et al. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem. 2012;287(15):11629- 11641. doi: 10.1074/jbc.M111.338673Larkin KA, Zafra I, Golden A. Copa-1 mutants experience heightened endoplasmic reticulum stress sensitivity in a C. elegans COPA syndrome model. MicroPubl Biol. 2023;2023:10.17912/micropub. biology.000696. doi: 10.17912/micropub.biology.000696Larkin KA, Zafra I, Golden A. Copa-1 mutants experience heightened endoplasmic reticulum stress sensitivity in a C. elegans COPA syndrome model. MicroPubl Biol. 2023;2023:10.17912/micropub. biology.000696. doi: 10.17912/micropub.biology.000696Simchoni N, Vogel TP, Shum AK. COPA syndrome from diagnosis to treatment: A clinician’s guide. Rheum Dis Clin North Am. 2023;49(4):789-804. doi: 10.1016/j.rdc.2023.06.005Simchoni N, Vogel TP, Shum AK. COPA syndrome from diagnosis to treatment: A clinician’s guide. Rheum Dis Clin North Am. 2023;49(4):789-804. doi: 10.1016/j.rdc.2023.06.005Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T. Interstitial lung disease in connective tissue diseases: Survival patterns in a population-based cohort. J Clin Med. 2021;10(21):4830. doi: 10.3390/jcm10214830Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T. Interstitial lung disease in connective tissue diseases: Survival patterns in a population-based cohort. J Clin Med. 2021;10(21):4830. doi: 10.3390/jcm10214830Насонов ЕЛ, Ананьева ЛП, Белевский АС. Интерстициальные заболевания легких и аутоиммунитет. Научно-практическая ревматология. 2025;63(2):119-128. doi: 10.47360/1995-4484-2025-119-128Nasonov EL, Ananyeva LP, Belevsky AS. Interstitial lung diseases and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2025-119-128Campitiello R, Soldano S, Gotelli E, Hysa E, Montagna P, Casabella A, et al. The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: A systematic review. Autoimmun Rev. 2024;23(10):103637. doi: 10.1016/j.autrev.2024.103637Campitiello R, Soldano S, Gotelli E, Hysa E, Montagna P, Casabella A, et al. The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: A systematic review. Autoimmun Rev. 2024;23(10):103637. doi: 10.1016/j.autrev.2024.103637Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol. 2015;11(1):e1004005. doi: 10.1371/journal.pcbi.1004005Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol. 2015;11(1):e1004005. doi: 10.1371/journal.pcbi.1004005Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol. 2002;26(5):549-557. doi: 10.1165/ajrcmb.26.5.4683Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol. 2002;26(5):549-557. doi: 10.1165/ajrcmb.26.5.4683Soldano S, Trombetta AC, Contini P, Tomatis V, Ruaro B, Brizzolara R, et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum Dis. 2018;77(12):1842-1845. doi: 10.1136/annrheumdis-2018-213648Soldano S, Trombetta AC, Contini P, Tomatis V, Ruaro B, Brizzolara R, et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum Dis. 2018;77(12):1842-1845. doi: 10.1136/annrheumdis-2018-213648Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128. doi: 10.1186/ar3066Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128. doi: 10.1186/ar3066Герасимова ЕВ, Богатырева АИ, Кириченко ТВ, Попкова ТВ, Шаяхметова РУ, Ананьева ЛП, и др. Воспалительный ответ культивируемых макрофагов пациентов с нелеченной системной склеродермией. Научно-практическая ревматология. 2025;63(2):176-182. doi: 10.47360/1995-4484-2025-176-182Gerasimova EV, Bogatyreva AI, Kirichenko TV, Popkova TV, Shayakhmetova RU, Ananyeva LP, et al. Inflammatory response of cultured macrophages in treatmentnaive patients with systemic sclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2025;63(2):176-182 (In Russ.). doi: 10.47360/1995-4484-2025-176-182Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438-449. doi: 10.1378/chest.14-1120Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438-449. doi: 10.1378/chest.14-1120Ying Z, Elyse EL, Yinping F, Shanshan D, Huiping L, Robert PB. Clinical characteristics of sarcoidosis patients in the United States versus China. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(3):209- 216. doi: 10.36141/svdld.v34i3.5727Ying Z, Elyse EL, Yinping F, Shanshan D, Huiping L, Robert PB. Clinical characteristics of sarcoidosis patients in the United States versus China. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(3):209- 216. doi: 10.36141/svdld.v34i3.5727Locke LW, Crouser ED, White P, Julian MW, Caceres EG, Papp AC, et al. IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am J Respir Cell Mol Biol. 2019;60(1):84-95. doi: 10.1165/rcmb.2018-0053OCLocke LW, Crouser ED, White P, Julian MW, Caceres EG, Papp AC, et al. IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am J Respir Cell Mol Biol. 2019;60(1):84-95. doi: 10.1165/rcmb.2018-0053OCShamaei M, Mortaz E, Pourabdollah M, Garssen J, Tabarsi P, Velayati A, et al. Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. Hum Immunol. 2018;79(1):63-69. doi: 10.1016/j.humimm.2017.10.009Shamaei M, Mortaz E, Pourabdollah M, Garssen J, Tabarsi P, Velayati A, et al. Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. Hum Immunol. 2018;79(1):63-69. doi: 10.1016/j.humimm.2017.10.009Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99-106. doi: 10.1038/nm1332Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99-106. doi: 10.1038/nm1332Wojtan P, Mierzejewski M, Osińska I, Domagała-Kulawik J. Macrophage polarization in interstitial lung diseases. Cent Eur J Immunol. 2016;41(2):159-164. doi: 10.5114/ceji.2016.60990Wojtan P, Mierzejewski M, Osińska I, Domagała-Kulawik J. Macrophage polarization in interstitial lung diseases. Cent Eur J Immunol. 2016;41(2):159-164. doi: 10.5114/ceji.2016.60990Standiford TJ. Macrophage polarization in sarcoidosis: An unexpected accomplice? Am J Respir Cell Mol Biol. 2019;60(1):9-10. doi: 10.1165/rcmb.2018-0298EDStandiford TJ. Macrophage polarization in sarcoidosis: An unexpected accomplice? Am J Respir Cell Mol Biol. 2019;60(1):9-10. doi: 10.1165/rcmb.2018-0298EDSahoo DH, Bandyopadhyay D, Xu M, Pearson K, Parambil JG, Lazar CA, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145-1150. doi: 10.1183/09031936.00195010Sahoo DH, Bandyopadhyay D, Xu M, Pearson K, Parambil JG, Lazar CA, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145-1150. doi: 10.1183/09031936.00195010Prokop S, Heppner FL, Goebel HH, Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol. 2011;178(3):1279-1286. doi: 10.1016/j.ajpath.2010.11.065Prokop S, Heppner FL, Goebel HH, Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol. 2011;178(3):1279-1286. doi: 10.1016/j.ajpath.2010.11.065Nashatyreva MS, Trofimenko IN, Chernyak BA, Avdeev SN. Pulmonary fibrosis and progressive pulmonary fibrosis in a prospective registry of interstitial lung diseases in Eastern Siberia. Life (Basel). 2023;13(1):212. doi: 10.3390/life13010212Nashatyreva MS, Trofimenko IN, Chernyak BA, Avdeev SN. Pulmonary fibrosis and progressive pulmonary fibrosis in a prospective registry of interstitial lung diseases in Eastern Siberia. Life (Basel). 2023;13(1):212. doi: 10.3390/life13010212Montero IE, Hernandez-Gonzalez F, Sellares J. Epidemiology and prognosis of progressive pulmonary fibrosis: A literature review. Pulm Ther. 2025;11(3):347-363. doi: 10.1007/s41030-025-00302-5Montero IE, Hernandez-Gonzalez F, Sellares J. Epidemiology and prognosis of progressive pulmonary fibrosis: A literature review. Pulm Ther. 2025;11(3):347-363. doi: 10.1007/s41030-025-00302-5Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. doi: 10.1183/13993003.02571-2021Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. doi: 10.1183/13993003.02571-2021Kondoh Y, Ito T, Saito K, Bao H, Sakamoto W. Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database. Respir Investig. 2024;62(4):702-709. doi: 10.1016/j.resinv.2024.05.005Kondoh Y, Ito T, Saito K, Bao H, Sakamoto W. Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database. Respir Investig. 2024;62(4):702-709. doi: 10.1016/j.resinv.2024.05.005Peng D, Li J, Li Y, Bai L, Xiong A, He X, et al. MMP14high macrophages orchestrate progressive pulmonary fibrosis in SR-Aginduced hypersensitivity pneumonitis. Pharmacol Res. 2024;200:107070. doi: 10.1016/j.phrs.2024.107070Peng D, Li J, Li Y, Bai L, Xiong A, He X, et al. MMP14high macrophages orchestrate progressive pulmonary fibrosis in SR-Aginduced hypersensitivity pneumonitis. Pharmacol Res. 2024;200:107070. doi: 10.1016/j.phrs.2024.107070Wang J, Zhang L, Luo L, He P, Xiong A, Jiang M, et al. Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis. Cell Death Discov. 2022;8(1):38. doi: 10.1038/s41420-022-00831-xWang J, Zhang L, Luo L, He P, Xiong A, Jiang M, et al. Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis. Cell Death Discov. 2022;8(1):38. doi: 10.1038/s41420-022-00831-xLionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi: 10.1002/art.34562Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi: 10.1002/art.34562Lamprecht P, Gross WL. Current knowledge on cellular interactions in the WG-granuloma. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S49-S51.Lamprecht P, Gross WL. Current knowledge on cellular interactions in the WG-granuloma. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S49-S51.Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, et al. B lymphocyte maturation in Wegener’s granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis. 2006;65(7):859-864. doi: 10.1136/ard.2005.044909Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, et al. B lymphocyte maturation in Wegener’s granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis. 2006;65(7):859-864. doi: 10.1136/ard.2005.044909Hilhorst M, Shirai T, Berry G, Goronzy JJ, Weyand CM. T cellmacrophage interactions and granuloma formation in vasculitis. Front Immunol. 2014;5:432. doi: 10.3389/fimmu.2014.00432Hilhorst M, Shirai T, Berry G, Goronzy JJ, Weyand CM. T cellmacrophage interactions and granuloma formation in vasculitis. Front Immunol. 2014;5:432. doi: 10.3389/fimmu.2014.00432Capraru D, Müller A, Csernok E, Gross WL, Holl-Ulrich K, Northfield J, et al. Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener’s granulomatosis. Clin Immunol. 2008;127(2):144-150. doi: 10.1016/j.clim.2007.12.004Capraru D, Müller A, Csernok E, Gross WL, Holl-Ulrich K, Northfield J, et al. Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener’s granulomatosis. Clin Immunol. 2008;127(2):144-150. doi: 10.1016/j.clim.2007.12.004Бекетова ТВ. Микроскопический полиангиит, ассоциированный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Терапевтический архив. 2015;87(5):33-46. doi: 10.17116/terarkh201587533-46Beketova TV. Microscopic polyangiitis associated with antineutrophil cytoplasmic antibodies: Clinical features. Terapevticheskii arkhiv. 2015;87(5):33-46 (In Russ.). doi: 10.17116/terarkh201587533-46Casal Moura M, Tandon YK, Hartman TE, Ryu JH, Baqir M. Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: Chest CT patterns and correlation with survival. Semin Arthritis Rheum. 2025;73:152726. doi: 10.1016/j.semarthrit.2025.152726Casal Moura M, Tandon YK, Hartman TE, Ryu JH, Baqir M. Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: Chest CT patterns and correlation with survival. Semin Arthritis Rheum. 2025;73:152726. doi: 10.1016/j.semarthrit.2025.152726Arulkumaran N, Periselneris N, Gaskin G, Strickland N, Ind PW, Pusey CD, et al. Interstitial lung disease and ANCA-associated vasculitis: A retrospective observational cohort study. Rheumatology (Oxford). 2011;50(11):2035-2043. doi: 10.1093/rheumatology/ker236Arulkumaran N, Periselneris N, Gaskin G, Strickland N, Ind PW, Pusey CD, et al. Interstitial lung disease and ANCA-associated vasculitis: A retrospective observational cohort study. Rheumatology (Oxford). 2011;50(11):2035-2043. doi: 10.1093/rheumatology/ker236Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCAassociated vasculitis: From pathogenesis to diagnosis. Clin Kidney J. 2015;8(3):343-350. doi: 10.1093/ckj/sfv020Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCAassociated vasculitis: From pathogenesis to diagnosis. Clin Kidney J. 2015;8(3):343-350. doi: 10.1093/ckj/sfv020Falk RJ, Terrell RS, Charles LA. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115-4119. doi: 10.1073/pnas.87.11.4115Falk RJ, Terrell RS, Charles LA. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115-4119. doi: 10.1073/pnas.87.11.4115Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol. 1994;95(2):244-250. doi: 10.1111/j.1365-2249.1994.tb06518.xCsernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol. 1994;95(2):244-250. doi: 10.1111/j.1365-2249.1994.tb06518.xCharles LA, Falk RJ, Jennette JC. Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes. J Leukoc Biol. 1992;51(1):65-68. doi: 10.1002/jlb.51.1.65Charles LA, Falk RJ, Jennette JC. Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes. J Leukoc Biol. 1992;51(1):65-68. doi: 10.1002/jlb.51.1.65Weidner S, Neupert W, Goppelt-Struebe M, Rupprecht HD. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 2001;44(7):1698-1706. doi: 10.1002/1529-0131(200107)44:7<1698::AIDART294>3.0.CO;2-JWeidner S, Neupert W, Goppelt-Struebe M, Rupprecht HD. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 2001;44(7):1698-1706. doi: 10.1002/1529-0131(200107)44:7<1698::AIDART294>3.0.CO;2-JO’Brien EC, Abdulahad WH, Rutgers A, Huitema MG, O’Reilly VP, Coughlan AM, et al. Intermediate monocytes in ANCA vasculitis: Increased surface expression of ANCA autoantigens and IL-1β secretion in response to anti-MPO antibodies. Sci Rep. 2015;5:11888. doi: 10.1038/srep11888O’Brien EC, Abdulahad WH, Rutgers A, Huitema MG, O’Reilly VP, Coughlan AM, et al. Intermediate monocytes in ANCA vasculitis: Increased surface expression of ANCA autoantigens and IL-1β secretion in response to anti-MPO antibodies. Sci Rep. 2015;5:11888. doi: 10.1038/srep11888Popat RJ, Hakki S, Thakker A, Coughlan AM, Watson J, Little MA, et al. Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. JCI Insight. 2017;2(2):e87379. doi: 10.1172/jci.insight.87379Popat RJ, Hakki S, Thakker A, Coughlan AM, Watson J, Little MA, et al. Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. JCI Insight. 2017;2(2):e87379. doi: 10.1172/jci.insight.87379Zhao L, David MZ, Hyjek E, Chang A, Meehan SM. M2 macrophage infiltrates in the early stages of ANCA-associated pauciimmune necrotizing GN. Clin J Am Soc Nephrol. 2015;10(1):54- 62. doi: 10.2215/CJN.03230314Zhao L, David MZ, Hyjek E, Chang A, Meehan SM. M2 macrophage infiltrates in the early stages of ANCA-associated pauciimmune necrotizing GN. Clin J Am Soc Nephrol. 2015;10(1):54- 62. doi: 10.2215/CJN.03230314Moran SM, Monach PA, Zgaga L, Cuthbertson D, Carette S, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2020;35(2):283-291. doi: 10.1093/ndt/gfy300Moran SM, Monach PA, Zgaga L, Cuthbertson D, Carette S, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2020;35(2):283-291. doi: 10.1093/ndt/gfy300O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol. 2016;27(9):2906-2916. doi: 10.1681/ASN.2015050511O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, et al. Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol. 2016;27(9):2906-2916. doi: 10.1681/ASN.2015050511Aendekerk JP, Timmermans SAMEG, Busch MH, Potjewijd J, Heeringa P, Damoiseaux JGMC, et al.; Limburg Renal Registry. Urinary soluble CD163 and disease activity in biopsy-proven ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(12):1740-1748. doi: 10.2215/CJN.07210520Aendekerk JP, Timmermans SAMEG, Busch MH, Potjewijd J, Heeringa P, Damoiseaux JGMC, et al.; Limburg Renal Registry. Urinary soluble CD163 and disease activity in biopsy-proven ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(12):1740-1748. doi: 10.2215/CJN.07210520Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al.; European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int. 2002;61(1):80-89. doi: 10.1046/j.1523-1755.2002.00089.xHauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al.; European Vasculitis Study Group (EUVAS). Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroups. Kidney Int. 2002;61(1):80-89. doi: 10.1046/j.1523-1755.2002.00089.xde Souza AWS, van Timmeren M, Sanders JS, Stegeman C, Heeringa P, Kallenberg CGM, et al. M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis. Arthritis Res Ther. 2017;19(1):100. doi: 10.1186/s13075-017-1310-4de Souza AWS, van Timmeren M, Sanders JS, Stegeman C, Heeringa P, Kallenberg CGM, et al. M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis. Arthritis Res Ther. 2017;19(1):100. doi: 10.1186/s13075-017-1310-4Matsuda S, Kotani T, Kuwabara H, Suzuka T, Kiboshi T, Fukui K, et al. CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease. Rheumatology (Oxford). 2021;60(10):4643-4653. doi: 10.1093/rheumatology/keab064Matsuda S, Kotani T, Kuwabara H, Suzuka T, Kiboshi T, Fukui K, et al. CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease. Rheumatology (Oxford). 2021;60(10):4643-4653. doi: 10.1093/rheumatology/keab064Vegting Y, Vogt L, Anders HJ, de Winther MPJ, Bemelman FJ, Hilhorst ML. Monocytes and macrophages in ANCA-associated vasculitis. Autoimmun Rev. 2021;20(10):102911. doi: 10.1016/j.autrev.2021.102911Vegting Y, Vogt L, Anders HJ, de Winther MPJ, Bemelman FJ, Hilhorst ML. Monocytes and macrophages in ANCA-associated vasculitis. Autoimmun Rev. 2021;20(10):102911. doi: 10.1016/j.autrev.2021.102911Ohlsson SM, Linge CP, Gullstrand B, Lood C, Johansson A, Ohlsson S, et al. Serum from patients with systemic vasculitis induces alternatively activated macrophage M2c polarization. Clin Immunol. 2014;152(1-2):10-19. doi: 10.1016/j.clim.2014.02.016Ohlsson SM, Linge CP, Gullstrand B, Lood C, Johansson A, Ohlsson S, et al. Serum from patients with systemic vasculitis induces alternatively activated macrophage M2c polarization. Clin Immunol. 2014;152(1-2):10-19. doi: 10.1016/j.clim.2014.02.016Vegting Y, Jongejan A, Neele AE, Claessen N, Sela G, Prange KHM, et al. Infiltrative classical monocyte-derived and SPP1 lipid-associated macrophages mediate inflammation and fibrosis in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2025;40(7):1416-1427. doi: 10.1093/ndt/gfae292Vegting Y, Jongejan A, Neele AE, Claessen N, Sela G, Prange KHM, et al. Infiltrative classical monocyte-derived and SPP1 lipid-associated macrophages mediate inflammation and fibrosis in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2025;40(7):1416-1427. doi: 10.1093/ndt/gfae292Hilhorst M, Kok HM, Broekhuizen R, van Paassen P, van Breda Vriesman P, Goldschmeding R, et al.; Limburg Renal Registry. Connective tissue growth factor and the cicatrization of cellular crescents in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2015;30(8):1291-1299. doi: 10.1093/ndt/gfv088Hilhorst M, Kok HM, Broekhuizen R, van Paassen P, van Breda Vriesman P, Goldschmeding R, et al.; Limburg Renal Registry. Connective tissue growth factor and the cicatrization of cellular crescents in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2015;30(8):1291-1299. doi: 10.1093/ndt/gfv088Gallo JR, Froullet C, Varizat A, Calvo RA, Pisoni C, Cosatti M, et al. Clinical and imaging pulmonary manifestations in IgG4- related disease. J Clin Rheumatol. 2025;31(2):47-52. doi: 10.1097/RHU.0000000000002160Gallo JR, Froullet C, Varizat A, Calvo RA, Pisoni C, Cosatti M, et al. Clinical and imaging pulmonary manifestations in IgG4- related disease. J Clin Rheumatol. 2025;31(2):47-52. doi: 10.1097/RHU.0000000000002160Furukawa S, Moriyama M, Miyake K, Nakashima H, Tanaka A, Maehara T, et al. Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci Rep. 2017;7:42413. doi: 10.1038/srep42413Furukawa S, Moriyama M, Miyake K, Nakashima H, Tanaka A, Maehara T, et al. Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci Rep. 2017;7:42413. doi: 10.1038/srep42413Chinju A, Moriyama M, Kakizoe-Ishiguro N, Chen H, Miyahara Y, Haque ASMR, et al. CD163+ M2 macrophages promote fibrosis in IgG4-related disease via Toll-like receptor 7/interleukin-1 receptor-associated kinase 4/NF-κB signaling. Arthritis Rheumatol. 2022;74(5):892-901. doi: 10.1002/art.42043Chinju A, Moriyama M, Kakizoe-Ishiguro N, Chen H, Miyahara Y, Haque ASMR, et al. CD163+ M2 macrophages promote fibrosis in IgG4-related disease via Toll-like receptor 7/interleukin-1 receptor-associated kinase 4/NF-κB signaling. Arthritis Rheumatol. 2022;74(5):892-901. doi: 10.1002/art.42043Hu M, Yao Z, Xu L, Peng M, Deng G, Liu L, et al. M2 macrophage polarization in systemic sclerosis fibrosis: Pathogenic mechanisms and therapeutic effects. Heliyon. 2023;9(5):e16206. doi: 10.1016/j.heliyon.2023.e16206Hu M, Yao Z, Xu L, Peng M, Deng G, Liu L, et al. M2 macrophage polarization in systemic sclerosis fibrosis: Pathogenic mechanisms and therapeutic effects. Heliyon. 2023;9(5):e16206. doi: 10.1016/j.heliyon.2023.e16206Bahram Yazdroudi F, Malek A. Reducing M2 macrophage in lung fibrosis by controlling anti-M1 agent. Sci Rep. 2025;15(1):4120. doi: 10.1038/s41598-024-76561-0Bahram Yazdroudi F, Malek A. Reducing M2 macrophage in lung fibrosis by controlling anti-M1 agent. Sci Rep. 2025;15(1):4120. doi: 10.1038/s41598-024-76561-0Redente EF, Keith RC, Janssen W, Henson PM, Ortiz LA, Downey GP, et al. Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am J Respir Cell Mol Biol. 2014;50(4):825-837. doi: 10.1165/rcmb.2013-0386OCRedente EF, Keith RC, Janssen W, Henson PM, Ortiz LA, Downey GP, et al. Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am J Respir Cell Mol Biol. 2014;50(4):825-837. doi: 10.1165/rcmb.2013-0386OCChoi YJ, Kim MJ, Lee YJ, Choi M, Shim WS, Park M, et al. Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK inhibitors. Theranostics. 2025;15(3):875-893. doi: 10.7150/thno.100970Choi YJ, Kim MJ, Lee YJ, Choi M, Shim WS, Park M, et al. Prevention of radiotherapy-induced pro-tumorigenic microenvironment by SFK inhibitors. Theranostics. 2025;15(3):875-893. doi: 10.7150/thno.100970Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, et al. Inhibition of the progression of skin inflammation, fibrosis, and vascular injury by blockade of the CX3 CL1/ CX 3 CR1 pathway in experimental mouse models of systemic sclerosis. Arthritis Rheumatol. 2019;71(11):1923-1934. doi: 10.1002/art.41009Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, et al. Inhibition of the progression of skin inflammation, fibrosis, and vascular injury by blockade of the CX3 CL1/ CX 3 CR1 pathway in experimental mouse models of systemic sclerosis. Arthritis Rheumatol. 2019;71(11):1923-1934. doi: 10.1002/art.41009Zhang Z, Wu Y, Wu B, Qi Q, Li H, Lu H, et al. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Arthritis Res Ther. 2019;21(1):290. doi: 10.1186/s13075-019-2074-9Zhang Z, Wu Y, Wu B, Qi Q, Li H, Lu H, et al. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Arthritis Res Ther. 2019;21(1):290. doi: 10.1186/s13075-019-2074-9Stenström M, Nyhlén HC, Törngren M, Liberg D, Sparre B, Tuvesson H, Eriksson H, et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J Dermatol Sci. 2016;83(1):52-59. doi: 10.1016/j.jdermsci.2016.04.006Stenström M, Nyhlén HC, Törngren M, Liberg D, Sparre B, Tuvesson H, Eriksson H, et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J Dermatol Sci. 2016;83(1):52-59. doi: 10.1016/j.jdermsci.2016.04.006Luong VH, Chino T, Oyama N, Matsushita T, Sasaki Y, Ogura D, et al. Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. Arthritis Res Ther. 2018;20(1):46. doi: 10.1186/s13075-018-1534-yLuong VH, Chino T, Oyama N, Matsushita T, Sasaki Y, Ogura D, et al. Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. Arthritis Res Ther. 2018;20(1):46. doi: 10.1186/s13075-018-1534-yPark GT, Kwon YW, Lee TW, Kwon SG, Ko HC, Kim MB, et al. Formyl peptide receptor 2 activation ameliorates dermal fibrosis and inflammation in bleomycin-induced scleroderma. Front Immunol. 2019;10:2095. doi: 10.3389/fimmu.2019.02095Park GT, Kwon YW, Lee TW, Kwon SG, Ko HC, Kim MB, et al. Formyl peptide receptor 2 activation ameliorates dermal fibrosis and inflammation in bleomycin-induced scleroderma. Front Immunol. 2019;10:2095. doi: 10.3389/fimmu.2019.02095Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Miura S, et al. Glycyrrhizin ameliorates fibrosis, vasculopathy, and inflammation in animal models of systemic sclerosis. J Invest Dermatol. 2017;137(3):631-640. doi: 10.1016/j.jid.2016.08.037Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Miura S, et al. Glycyrrhizin ameliorates fibrosis, vasculopathy, and inflammation in animal models of systemic sclerosis. J Invest Dermatol. 2017;137(3):631-640. doi: 10.1016/j.jid.2016.08.037Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012;180(1):165- 176. doi: 10.1016/j.ajpath.2011.09.013Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012;180(1):165- 176. doi: 10.1016/j.ajpath.2011.09.013Sakkas LI. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis. Drug Des Dev Ther. 2016;10:2723- 2728. doi: 10.2147/DDDT.S99696Sakkas LI. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis. Drug Des Dev Ther. 2016;10:2723- 2728. doi: 10.2147/DDDT.S99696Maier C, Ramming A, Bergmann C, Weinkam R, Kittan N, Schett G, et al. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis. 2017;76(6):1133- 1141. doi: 10.1136/annrheumdis-2016-210189Maier C, Ramming A, Bergmann C, Weinkam R, Kittan N, Schett G, et al. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis. 2017;76(6):1133- 1141. doi: 10.1136/annrheumdis-2016-210189Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol. 2020;178:114103. doi: 10.1016/j.bcp.2020.114103Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol. 2020;178:114103. doi: 10.1016/j.bcp.2020.114103Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823Toda M, Mizuguchi S, Minamiyama Y, Yamamoto-Oka H, Aota T, Kubo S, et al. Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts. J Clin Biochem Nutr. 2018;63(1):58-65. doi: 10.3164/jcbn.17-111Toda M, Mizuguchi S, Minamiyama Y, Yamamoto-Oka H, Aota T, Kubo S, et al. Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts. J Clin Biochem Nutr. 2018;63(1):58-65. doi: 10.3164/jcbn.17-111Guo Z, Li S, Zhang N, Kang Q, Zhai H. Schisandra inhibit bleomycin-induced idiopathic pulmonary fibrosis in rats via suppressing M2 macrophage polarization. BioMed Res Int. 2020; 2020:5137349. doi: 10.1155/2020/5137349Guo Z, Li S, Zhang N, Kang Q, Zhai H. Schisandra inhibit bleomycin-induced idiopathic pulmonary fibrosis in rats via suppressing M2 macrophage polarization. BioMed Res Int. 2020; 2020:5137349. doi: 10.1155/2020/5137349Wang J, Xu L, Xiang Z, Ren Y, Zheng X, Zhao Q, et al. Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206+ M2-like macrophage polarization. Cell Death Dis. 2020;11(2):136. doi: 10.1038/s41419-020-2329-zWang J, Xu L, Xiang Z, Ren Y, Zheng X, Zhao Q, et al. Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206+ M2-like macrophage polarization. Cell Death Dis. 2020;11(2):136. doi: 10.1038/s41419-020-2329-zCodullo V, Cova E, Pandolfi L, Breda S, Morosini M, Frangipane V, et al. Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. J Control Release. 2019;310:198-208. doi: 10.1016/j.jconrel.2019.08.015Codullo V, Cova E, Pandolfi L, Breda S, Morosini M, Frangipane V, et al. Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. J Control Release. 2019;310:198-208. doi: 10.1016/j.jconrel.2019.08.015Burkart C, Seikkula M, Eide L, Paz S, Chu D, Polizzi C, et al. ATYR1923 modulates the inflammatory response in experimental models of interstitial lung disease. Am J Respir Crit. Care Med. 2019;199:A2421. doi: 10.1164/AJRCCM-CONFERENCE.2019.199.1_MEETINGABSTRACTS.A2421Burkart C, Seikkula M, Eide L, Paz S, Chu D, Polizzi C, et al. ATYR1923 modulates the inflammatory response in experimental models of interstitial lung disease. Am J Respir Crit. Care Med. 2019;199:A2421. doi: 10.1164/AJRCCM-CONFERENCE.2019.199.1_MEETINGABSTRACTS.A2421Ghazipura M, Macrea M, Herman D, Barnes H, Knight SL, Silver RM, et al. Tocilizumab in patients with systemic sclerosisassociated interstitial lung disease: A systematic review and metaanalysis. Ann Am Thorac Soc. 2024;21(2):328-337. doi: 10.1513/AnnalsATS.202301-056OCGhazipura M, Macrea M, Herman D, Barnes H, Knight SL, Silver RM, et al. Tocilizumab in patients with systemic sclerosisassociated interstitial lung disease: A systematic review and metaanalysis. Ann Am Thorac Soc. 2024;21(2):328-337. doi: 10.1513/AnnalsATS.202301-056OCZongfei J, Lijuan Z, Ying S, Dongmei L, Sifan W, Xiufang K, et al. Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: Insights from a prospective IgG4-related disease registry. Ther Adv Chronic Dis. 2021;12:20406223211028776. doi: 10.1177/20406223211028776Zongfei J, Lijuan Z, Ying S, Dongmei L, Sifan W, Xiufang K, et al. Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: Insights from a prospective IgG4-related disease registry. Ther Adv Chronic Dis. 2021;12:20406223211028776. doi: 10.1177/20406223211028776Akiyama M, Hayashi Y, Suzuki K, Takeuchi T, Kaneko Y. Successful treatment of IgG4-related disease with tocilizumab monotherapy. Autoimmun Rev. 2023;22(4):103296. doi: 10.1016/j.autrev.2023.103296Akiyama M, Hayashi Y, Suzuki K, Takeuchi T, Kaneko Y. Successful treatment of IgG4-related disease with tocilizumab monotherapy. Autoimmun Rev. 2023;22(4):103296. doi: 10.1016/j.autrev.2023.103296Ong J, Brown S, Gilbertson M, Grigoriadis G, Simpson I, Vilcassim S, et al. Two cases of refractory IgG4-related disease successfully treated with tocilizumab. Ann Hematol. 2022;101(7):1593-1594. doi: 10.1007/s00277-022-04787-xOng J, Brown S, Gilbertson M, Grigoriadis G, Simpson I, Vilcassim S, et al. Two cases of refractory IgG4-related disease successfully treated with tocilizumab. Ann Hematol. 2022;101(7):1593-1594. doi: 10.1007/s00277-022-04787-xRey-Gallardo A, Escribano C, Delgado-Martín C, Rodriguez-Fernández JL, Gerardy-Schahn R, Rutishauser U, et al. Polysialylated neuropilin-2 enhances human dendritic cell migration through the basic C-terminal region of CCL21. Glycobiology. 2010;20(9):1139-1146. doi: 10.1093/glycob/cwq078Rey-Gallardo A, Escribano C, Delgado-Martín C, RodriguezFernández JL, Gerardy-Schahn R, Rutishauser U, et al. Polysialylated neuropilin-2 enhances human dendritic cell migration through the basic C-terminal region of CCL21. Glycobiology. 2010;20(9):1139-1146. doi: 10.1093/glycob/cwq078Rey-Gallardo A, Delgado-Martín C, Gerardy-Schahn R, Rodríguez-Fernández JL, Vega MA. Polysialic acid is required for neuropilin-2a/b-mediated control of CCL21-driven chemotaxis of mature dendritic cells and for their migration in vivo. Glycobiology. 2011;21:655-662. doi: 10.1093/glycob/cwq216Rey-Gallardo A, Delgado-Martín C, Gerardy-Schahn R, Rodríguez-Fernández JL, Vega MA. Polysialic acid is required for neuropilin-2a/b-mediated control of CCL21-driven chemotaxis of mature dendritic cells and for their migration in vivo. Glycobiology. 2011;21:655-662. doi: 10.1093/glycob/cwq216Förster S, Chong YE, Siefker D, Becker Y, Bao R, Escobedo E, et al. Development and characterization of a novel neuropilin-2 antibody for immunohistochemical staining of cancer and sarcoidosis tissue samples. Monoclon Antib Immunodiagn Immunother. 2023;42(5):157-165. doi: 10.1089/mab.2023.0007Förster S, Chong YE, Siefker D, Becker Y, Bao R, Escobedo E, et al. Development and characterization of a novel neuropilin-2 antibody for immunohistochemical staining of cancer and sarcoidosis tissue samples. Monoclon Antib Immunodiagn Immunother. 2023;42(5):157-165. doi: 10.1089/mab.2023.0007Siefker D, Xu Z, Ferrer M, Yu E, Guy L, Rauch K, et al. Efzofitimod: A novel therapeutic candidate for SSc-ILD. Eur Respir J. 2023;62(Suppl 67):PA419. doi: 10.1183/13993003.congress-2023.PA419Siefker D, Xu Z, Ferrer M, Yu E, Guy L, Rauch K, et al. Efzofitimod: A novel therapeutic candidate for SSc-ILD. Eur Respir J. 2023;62(Suppl 67):PA419. doi: 10.1183/13993003.congress-2023.PA419Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, et al. Efzofitimod for the treatment of pulmonary sarcoidosis. Chest. 2023;163(4):881-890. doi: 10.1016/j.chest.2022.10.037Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, et al. Efzofitimod for the treatment of pulmonary sarcoidosis. Chest. 2023;163(4):881-890. doi: 10.1016/j.chest.2022.10.037Obi ON, Baughman RP, Crouser ED, Julian MW, Locke LW, Chandrasekaran A, et al. Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis. ERJ Open Res. 2025;11(1):00536-2024. doi: 10.1183/23120541.00536-2024Obi ON, Baughman RP, Crouser ED, Julian MW, Locke LW, Chandrasekaran A, et al. Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis. ERJ Open Res. 2025;11(1):00536-2024. doi: 10.1183/23120541.00536-2024

The authors declare that there are no conflicts of interest present.